FDA approves Dupixent in COPD, opening ‘next chapter’ for Sanofi and Regeneron’s bestseller
The biggest drug driving Sanofi’s and Regeneron’s businesses is about to get a bit bigger.
On Friday, the FDA approved Dupixent as an add-on to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
